Beyond Crizotinib: A Systematic Review and Meta-Analysis of the Next-Generation ALK Inhibitors as First-Line Treatment for ALK-Translocated Lung Cancer

BACKGROUND: Second and third-generation ALK inhibitors (ALKIs) have been recently approved for ALK-translocated lung cancer treatment, improving - and expanding - the first-line scenario. METHODS: In this systematic review and metanalysis, we investigated the efficacy and safety of next-generation A...

Descripción completa

Detalles Bibliográficos
Autores principales: Giunta, Emilio Francesco, Signori, Alessio, West, Howard Jack, Metro, Giulio, Friedlaender, Alex, Parikh, Kaushal, Banna, Giuseppe Luigi, Addeo, Alfredo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239548/
https://www.ncbi.nlm.nih.gov/pubmed/35774122
http://dx.doi.org/10.3389/fonc.2022.921854

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239548/
https://www.ncbi.nlm.nih.gov/pubmed/35774122
http://dx.doi.org/10.3389/fonc.2022.921854

Ejemplares similares